With over 89377.0 Theratechnologies Inc. (THTX) shares trading Tuesday and a closing price of $0.98 on the day, the dollar volume was approximately $87589.45999999999. The shares have shown a negative half year performance of -56.65% and its price on 01/24/23 lost nearly -0.69%. Currently, there are 95.14M common shares owned by the public and among those 86.20M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for THTX have a consensus price objective of $4.60. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $2.34. But an upside of 89.11% will see the stock hit the forecast high price target while median target price for the stock is $3.75.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Insiders at the company have transacted a total of 11 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 6 of these insider trades were purchases, accounting for 116,500 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 20,000 shares.
The top 3 mutual fund holders in Theratechnologies Inc. are Caisse de Dépôt & Placement du Qu, Next Edge Biotech and Life Scienc, and Fidelity Nasdaq Composite Index F. Caisse de Dépôt & Placement du Qu owns 0.34 million shares of the company’s stock, all valued at over $0.3 million. The company sold -1.67 million shares recently to bring their total holdings to about 0.36% of the shares outstanding. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.05% of the shares outstanding.
Shares of Theratechnologies Inc. (NASDAQ: THTX) opened at $0.996, up $0.02 from a prior closing price of $0.98. However, the script later moved the day high at 0.9960, down -0.69%. The company’s stock has a 5-day price change of -5.30% and -49.85% over the past three months. THTX shares are trading 10.49% year to date (YTD), with the 12-month market performance down to -66.37% lower. It has a 12-month low price of $0.77 and touched a high of $3.26 over the same period. THTX has an average intraday trading volume of 380.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.58%, -27.66%, and -52.09% respectively.
Institutional ownership of Theratechnologies Inc. (NASDAQ: THTX) shares accounts for 27.36% of the company’s 95.14M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $92.80M. The earnings-per-share (ttm) stands at -$0.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.56% over the week and 9.40% over the month.
Analysts forecast that Theratechnologies Inc. (THTX) will achieve an EPS of -$0.06 for the current quarter, -$0.07 for the next quarter and -$0.26 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.07 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.1 a year ago. Earnings per share for the fiscal year are expected to decrease by -44.10%, and 53.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Theratechnologies Inc. (THTX) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 2 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the THTX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on November 17, 2022, with the firm’s price target at $9. Canaccord Genuity coverage for the Theratechnologies Inc. (THTX) stock in a research note released on July 29, 2021 offered a Hold rating with a price target of $3.
